Outcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study
Authors:
- Jacklyn LiuJLJacklyn Liu
- Yoko TakahashiYTYoko Takahashi
- Umar RehmanURUmar Rehman
- Mario Turri-ZanoniMario Turri-Zanoni
- Davide MattavelliDavide Mattavelli
- Nicholas CounsellNCNicholas Counsell
- Marco FerrariMFMarco Ferrari
- Vittorio RampinelliVRVittorio Rampinelli
- William VermiWVWilliam Vermi
- Davide LombardiDLDavide Lombardi
- Rami SaadeRSRami Saade
- Ki Wan ParkKPKi Wan Park
Open Access
Abstract
Background: Sinonasal undifferentiated carcinoma (SNUC) is an extremely rare, high-grade, and aggressive tumor of the sinonasal tract. Due to the rarity of this malignancy, current treatment guidelines are based on small and often/mainly single-center retrospective datasets. In the absence of a universally accepted standard of care for SNUC, treatment approaches vary across countries and institutions, reflecting real-world clinical practice. The primary aim of this study was to describe real-world treatment and outcomes for patients with confirmed SNUC. Methods: This was an international, multi-center, retrospective, observational cohort study that pooled patients into the largest SNUC dataset to date. Fifteen centers were enrolled to contribute data, including seven from Europe, four from the United States, three from the United Kingdom, and one from Canada. In the absence of a universally accepted standard of care for SNUC, treatment approaches varied across countries and institutions, reflecting real-world clinical practice. Patients included were those with histologically confirmed SNUC who were treated between 1997 and 2021. Results: This study yielded 485 patients treated for SNUC. The median age at diagnosis was 55.6 years (IQR: 44.5–67.6), and 63.7% were male. Most cases presented at advanced stages, with 70.8% as T4a or T4b. Overall survival (OS) outcomes were available for 412 patients, with a median follow-up of 26.0 months. The 5- and 10-year OS were 47.2% (95% CI: 40.8–53.3%) and 39.6% (95% CI: 32.5–46.6%), respectively. Advanced age, dichotomized T-stage (T4a/b vs. T1–3), M-stage, and orbital involvement were significant poor prognostic factors on univariable analysis (p’s < 0.01). On multivariable analysis, orbital involvement (HR: 2.73, 95% CI: 1.42–5.27, p = 0.003) and distance metastasis stage (HR: 3.00, 95% CI: 1.25–7.21, p = 0.014) were both independently associated with worse OS. Conclusions: This observational study presents the largest multi-center cohort analysis of SNUC to date, providing new insights into prognostic factors for a rare cancer treated at global centers of excellence. Orbital involvement and the presence of metastases are candidate independent risk factors associated with poorer OS.Keywords
Funding Information
- Head and Neck Cancer Research Trust
- Intramural Research Program of the NIH, Center for Cancer Research, National Cancer Institute
This publication has 28 references indexed in Scilit:
- Management of 80 sinonasal undifferentiated carcinomas. Retrospective multicentre study of the French Network of Rare Head and Neck Cancers (REFCOR)European Journal of Surgical Oncology, 2023
- Response to induction chemotherapy in sinonasal malignancies: A single‐institutional experienceHead & Neck, 2023
- Sinonasal undifferentiated carcinoma: Institutional trend toward induction chemotherapy followed by definitive chemoradiationHead & Neck, 2020
- Impact of induction chemotherapy and socioeconomics on sinonasal undifferentiated carcinoma survivalInternational Forum of Allergy & Rhinology, 2020
- Elective neck treatment in sinonasal undifferentiated carcinoma: Systematic review and meta‐analysisHead & Neck, 2020
- Identification of novel diagnostic markers for sinonasal undifferentiated carcinomaHead & Neck, 2019
- Outcomes and patterns of failure for sinonasal undifferentiated carcinoma (SNUC): The Mayo Clinic ExperienceHead & Neck, 2017
- Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: A retrospective reviewHead & Neck, 2014
- Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literatureEuropean Archives of Oto-Rhino-Laryngology, 2012
- Patterns of Failure After Combined-Modality Approaches Incorporating Radiotherapy for Sinonasal Undifferentiated Carcinoma of the Head and NeckInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008